...
首页> 外文期刊>Seminars in Thrombosis and Hemostasis >Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: Recent experience and outcome from North America
【24h】

Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: Recent experience and outcome from North America

机译:本地验证和平均凝血酶原时间的平均分配以及各种仪器的国际敏感性指数值:北美的最新经验和成果

获取原文
获取原文并翻译 | 示例

摘要

Warfarin dosing relies on accurate measurements of international normalized ratio (INR), which is calculated from the prothrombin time (PT), International Sensitivity Index international sensitivity index (ISI) of the thromboplastin, and the geometric mean of normal PT (MNPT). However, ISI assignments of certain reagent/instrument combinations are frequently unavailable, especially when the reagent and instrument are not from the same manufacturer. The effort to be in compliance with widely endorsed Clinical and Laboratory Standards Institute (CLSI) guidelines by locally verifying or assigning an ISI to an unsupported reagent/instrument combination is further hindered by the lack of US Food and Drug Administration (FDA)-approved certified plasmas designated for a particular reagent/instrument combination. The objectives of the study include development of a process to verify/assign ISI and MNPT of a single thromboplastin reagent from one manufacturer across multiple instruments including several from another manufacturer and across several campuses of a single institution, the Mayo Clinic. In this study, RecombiPlasTin 2G (R2G), was evaluated on the ACL TOP 700 (IL), STA-R Evolution, STA Compact, and STA Satellite. Random normal donor samples (n = 25) were used to verify/assign MNPT. A subset of the normal donors (n = 8) and 13 warfarin pools (INR range: 1.3-3.9), created from stable warfarin patient plasma, were used for ISI verification/assignment. The manufacturer's assigned ISI was first verified on the ACL TOP 700 (reference method), then assigned on three unsupported instruments using orthogonal regression analysis. The MNPT and manufacturer assigned ISI (11.0, 0.95) were verified on the ACL TOP 700 and subsequently assigned on the STA-R Evolution (11.6, 1.04); STA Compact (11.5, 1.02); and STA Satellite (10.9, 0.99). Linear correlations of the INR results from all the four instruments demonstrated an r 2 0.99. This process provides a reproducible approach to assigning ISIs on unsupported reagent/instrument combinations. Our data also confirm that ISIs of the same PT reagent differ significantly on different instruments, thus confirming the requirement for evaluations and validation of ISIs for different reagent/instrument combinations.
机译:华法林的剂量依赖于国际标准化比(INR)的准确测量,该标准化比由凝血酶原时间(PT),凝血活酶的国际敏感性指数国际敏感性指数(ISI)和正常PT的几何平均值(MNPT)计算得出。但是,某些试剂/仪器组合的ISI分配通常不可用,尤其是当试剂和仪器并非来自同一制造商时。缺乏美国食品药品监督管理局(FDA)批准的认证进一步阻碍了通过本地验证或将ISI分配给不受支持的试剂/仪器组合来符合广泛认可的临床和实验室标准协会(CLSI)指南的工作。指定用于特定试剂/仪器组合的血浆。该研究的目标包括开发一种过程,以验证/分配来自一家制造商的一种凝血酶原试剂的ISI和MNPT,涉及多种仪器,包括来自另一家制造商的多种仪器以及同一机构Mayo诊所的多个园区。在这项研究中,RecombiPlasTin 2G(R2G)在ACL TOP 700(IL),STA-R Evolution,STA Compact和STA Satellite上进行了评估。使用随机的正常供体样本(n = 25)来验证/分配MNPT。由稳定的华法令患者血浆创建的一部分正常供体(n = 8)和13个华法令库(INR范围:1.3-3.9)用于ISI验证/分配。制造商分配的ISI首先在ACL TOP 700(参考方法)上进行验证,然后使用正交回归分析在三台不受支持的仪器上进行分配。 MNPT和制造商分配的ISI(11.0,0.95)在ACL TOP 700上进行了验证,随后在STA-R Evolution(11.6,1.04)上进行了分配; STA Compact(11.5,1.02);和STA卫星(10.9,0.99)。所有四种仪器的INR结果的线性相关性均表明r 2> 0.99。此过程提供了一种可重现的方法,可以在不受支持的试剂/仪器组合上分配ISI。我们的数据还证实,同一PT试剂的ISI在不同的仪器上存在显着差异,从而确认了对不同试剂/仪器组合的ISI进行评估和验证的要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号